https://doi.org/10.55788/d2ddfbb7
The COVI-PRONE study (NCT04350723) sought to determine the efficacy and adverse events of awake prone positioning in adults with hypoxemic respiratory failure from COVID-19 [1,2]. It was a randomised, unblinded, parallel-group stratified clinical trial aiming to examine whether awake prone positioning in COVID-19 patients with hypoxemic respiratory failure reduced the risk of endotracheal requirement and mortality. The rationale for this trial lies in previous studies suggesting that the prone position reduces the risk of mortality in COVID-19 patients undergoing invasive mechanical ventilation for acute respiratory distress, but it is not known whether awake prone positioning can prevent intubation or improve survival. āIt is also not entirely known if awake prone positioning can actually cause harm due to delayed intubation,ā said Prof. Waleed Alhazzani (McMaster University, Canada) [1].
COVI-PRONE was conducted at 21 hospitals and included adults who required at least 40% oxygen or non-invasive positive pressure ventilation and had not received invasive mechanical ventilation. Participants (n=400) were randomised to either the intervention group (n=205; prone position 8ā10 hours per day) or the control group (n=195; no prone positioning). Baseline characteristics between the groups were similar in the use of pharmacological agents, such as steroids, antivirals, anticoagulants, or immunomodulators. The primary outcome was endotracheal intubation within 30 days of randomisation.
The results showed that the risk of endotracheal intubation did not significantly differ between groups at 30 days, with the prone group at 34.1% and the control group at 40.5% (HR 0.81; 95% 0.59ā1.12; not significant). Similarly, the risk of mortality at 60 days was similar between groups (HR 0.93; 95% CI 0.62ā1.40; not significant). No serious adverse events occurred in both groups, though the prone positioning group reported more overall adverse events (26 vs 0), mainly consisting of pain or discomfort attributable to the prone position.
The authors concluded that this trial provided robust evidence that awake prone positioning does not decrease the risk of endotracheal intubation or mortality in patients with acute hypoxemic respiratory failure due to COVID-19.
- Alhazzani W, et al. COVI-PRONE trial. Session A84, ATS International Conference 2022, San Francisco, CA, USA, 13ā18 May.
- Alhazzani W, et al. JAMA. 2022;327(21):2104ā2113.
Copyright Ā©2022 Medicom Medical Publishers
Posted on
Previous Article
« Mesenchymal stem cells offer no benefit in COVID-19 Next Article
Lung transplantation after COVID-19-associated ARDS »
« Mesenchymal stem cells offer no benefit in COVID-19 Next Article
Lung transplantation after COVID-19-associated ARDS »
Table of Contents: ATS 2022
Featured articles
Letter from the Editor
COVID-19
Nebulised aviptadil āfutileā in I-SPY COVID-19 trial
Lung transplantation after COVID-19-associated ARDS
Mesenchymal stem cells offer no benefit in COVID-19
Alpha-1 antitrypsin for ARDS secondary to severe COVID-19
Frailty prevalent 5 months following hospitalisation for COVID-19
Paediatric long COVID lacks definitions
Asthma Clinical Trial Updates
MANDALA and DENALI pattern success for albuterol-budesonide in asthma
ACOUSTICS data sounds good for adolescent asthma exacerbations
Type 2 asthma in children managed by dupilumab, despite atopic comorbidities
NAVIGATOR steers asthma patients to tezepelumab
High-intensity interval training slashes daily corticosteroids in asthma
Chronic Obstructive Pulmonary Disease
Threeās a crowd for triple therapy in COPD
Higher 1-year COPD mortality after hospitalisation for White patients
Reducing dyspnoea in chronic lung disease through weight loss
CT-evident mucus plugs in COPD associated with death
Home-based rehabilitation improves COPD: a randomised study
Highlighted Advances
Novel P2X3 antagonist can SOOTHE chronic cough
Colistimethate sodium PROMISing for non-cystic fibrosis bronchiectasis
Is avacopan better than prednisone for respiratory ANCA-associated vasculitis outcomes?
PAGANINI phase 2b data promising for eliapixant
POISE-3: Tranexamic acid for non-cardiac surgery
Obstructive sleep apnoea in most children with pulmonary hypertension
No screening evidence for COPD
Novel PDE4B inhibitor offers breakthrough for IPF
Hydrocortisone does not help preterm infants
CPAP temporarily supports pulmonary oxygenation in morbidly obese patients
ISAACC trial: CPAP controls blood pressure in ACS patients with severe OSA
Related Articles
October 29, 2020
CPAP withdrawal has negative consequences for sleep apnoea patients
June 16, 2021
Obstructive sleep apnoea associated with lower cognition
Ā© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com